The first implantable wireless device “CardioMEMS HF” has been approved by U. S. Food and Drug Administration to detect pulmonary artery pressure (PA) and heart rates in patients suffering from New York Heart Association (NHA) class II heart failure. This system provides remote monitoring of patient’s condition.
Heart failure is a disease in which heart is unable to pump sufficient blood that could meet the needs of body. It has been determined that nearly 5.8 million American people are suffering from heart failure. The life span of such patient could possibly be extended with lifestyle modifications in combination with drug therapy.
CardioMEMS HF System:
The CardioMEMS HF System can be implanted in body permanently at home by patients that can monitor;
- Systolic pulmonary artery pressure
- Diastolic pulmonary artery pressure
- Average pulmonary artery pressure.
The above data is then evaluated by physicians to judge the condition of patients that facilitate them for better decisions. In conclusion this will reduce the risk of patient hospitalization because after reviewing the condition of patients the physicians can alter drug therapy to meet the clinical needs of patients.
Parts of System:
This wireless system is comprises of following three parts;
A battery free implantable sensor
CardioMEMS Hospital and Patient Electronics Systems.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.